Primary central nervous system diffuse large B-cell lymphoma with MYC and BCL2 rearrangements associated with deep brain stimulation device.

IF 3.4 3区医学 Q1 PATHOLOGY Virchows Archiv Pub Date : 2024-10-18 DOI:10.1007/s00428-024-03948-9

Kirill A Lyapichev, Sri Bharathi Kavuri, Patrick J Karas, Laura Wu, Nahyun Jo, John Heymann, Hadi Yaziji, Jianli Dong, Farkhod Tursunbaev, Rasha Alfattal, Michelle Madden Felicella

{"title":"Primary central nervous system diffuse large B-cell lymphoma with MYC and BCL2 rearrangements associated with deep brain stimulation device.","authors":"Kirill A Lyapichev, Sri Bharathi Kavuri, Patrick J Karas, Laura Wu, Nahyun Jo, John Heymann, Hadi Yaziji, Jianli Dong, Farkhod Tursunbaev, Rasha Alfattal, Michelle Madden Felicella","doi":"10.1007/s00428-024-03948-9","DOIUrl":null,"url":null,"abstract":"<p><p>Primary central nervous system (CNS) diffuse large B-cell lymphoma with MYC and BCL2 rearrangements is a very rare lymphoma subtype. Deep brain stimulation is an effective minimally invasive therapeutic option for the treatment of refractory movement disorders, as well as some psychiatric disorders and chronic pain syndromes. Herein, we report a case of CNS lymphoma, which developed around an electrode of a deep brain stimulation (DBS) device. A 70-year-old woman with drug-resistant essential tremor was treated with bilateral thalamic DBS with significant symptomatic improvement over the following year. She presented to the emergency department with recurrent tremor, blurred vision, and confusion. Imaging showed a 4 cm heterogeneously enhancing centered around the DBS electrode. Pathologic evaluation and systemic workup confirmed a diagnosis of primary CNS diffuse large B-cell lymphoma. MYC and BCL2 rearrangements were identified. To our knowledge, this is the first reported case of a CNS lymphoma associated with a DBS electrode.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-024-03948-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Primary central nervous system (CNS) diffuse large B-cell lymphoma with MYC and BCL2 rearrangements is a very rare lymphoma subtype. Deep brain stimulation is an effective minimally invasive therapeutic option for the treatment of refractory movement disorders, as well as some psychiatric disorders and chronic pain syndromes. Herein, we report a case of CNS lymphoma, which developed around an electrode of a deep brain stimulation (DBS) device. A 70-year-old woman with drug-resistant essential tremor was treated with bilateral thalamic DBS with significant symptomatic improvement over the following year. She presented to the emergency department with recurrent tremor, blurred vision, and confusion. Imaging showed a 4 cm heterogeneously enhancing centered around the DBS electrode. Pathologic evaluation and systemic workup confirmed a diagnosis of primary CNS diffuse large B-cell lymphoma. MYC and BCL2 rearrangements were identified. To our knowledge, this is the first reported case of a CNS lymphoma associated with a DBS electrode.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

原发性中枢神经系统弥漫性大 B 细胞淋巴瘤，伴有 MYC 和 BCL2 重排，与脑深部刺激装置有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.